Top

Published in:

01-08-2013 | Hypertension and the Heart (PW de Leeuw and AH Gradman, Section Editors)

Aortic Valve Stenosis and Arterial Hypertension: A Synopsis in 2013

Authors: Vasiliki Katsi, Maria Marketou, Manolis S. Kallistratos, Thomas Makris, Athanasios J. Manolis, Dimitris Tousoulis, Christodoulos Stefanadis, Panos Vardas, Ioannis Kallikazaros

Published in: Current Hypertension Reports | Issue 4/2013

Abstract

Systemic hypertension and aortic valve stenosis (AVS) are both age-related diseases. The pathophysiology of AVS shares some similarities with essential hypertension, which might be the link between the two diseases. Although AS is usually related with low blood pressure levels, approximately one third of patients with severe AS suffer from arterial hypertension, a percentage that can increase up to 50 % according some studies. This review will summarize various aspects regarding the prevalence the pathophysiology and the natural history of those two diseases that seems to be linked, as well as the effect of blood pressure and antihypertensive treatment on various echocardiographic parameters in patients with AVS.

Otto CM, Lind BK, Kitzman DW, Gersh BJ, Siscovick DS. Association of aortic-valve sclerosis with cardiovascular mortality and morbidity in the elderly. N Engl J Med. 1999;341:142–7.PubMedCrossRef

Schwarz F, Baumann P, Manthey J, et al. The effect of aortic valve replacement on survival. Circulation. 1982;66:1105–10.PubMedCrossRef

Murphy ES, Lawson RM, Starr A, Rahimtoola SH. Severe aortic stenosis in patients 60 years of age or older: left ventricular function and 10-year survival after valve replacement. Circulation. 1981;64:II-184–8.

US Bureau of the Census. Statistical abstract of the United States: 2000. Washington, DC: US Government Printing Office; 2000.

Contralto AW, Levine SA. Aortic stenosis with special reference to angina pectoris and syncope. Ann Intern Med. 1937;1O:1636–53.

McGinn S, White PD. Clinical observations on aortic stenosis. Am JMed Sci. 1934;188:1–15.CrossRef

Ikram H, Marshall DE, Moore SM, Bones PJ. Hypertension in valvar aortic stenosis. NZ Med J. 1979;89:204–7.

Gaudino M, Alessandrini F, Glieca F, et al. Survival after aortic valve replacement for aortic stenosis: does left ventricular mass regression have a clinical correlate? Eur Heart J. 2005;26:51–7.PubMedCrossRef

Das P, Pocock C, Chambers J. The patient with a systolic murmur: severe aortic stenosis may be missed during cardiovascular examination. QJM. 2000;93:685–8.PubMedCrossRef

10.

Briand M, Dumesnil JG, Kadem L, et al. Reduced systemic arterial compliance impacts significantly LV afterload and functions in aortic stenosis: implications for diagnosis and treatment. J Am Coll Cardiol. 2005;46:291–8.PubMedCrossRef

11.

Antonini-Canterin F, Huang G, Cervesato E, et al. Symptomatic aortic stenosis: does systemic hypertension play an additional role? Hypertension. 2003;41:1268–72.PubMedCrossRef

12.

Ie E, Mook W, Shapiro AP. Systolic hypertension in critical aortic stenosis and the effect of valve replacement. J Hum Hypertens. 1996;10(2):65–7.PubMed

13.

Lindroos M, Kupari M, Valvanne J, Strandberg T, Heikkilä J, Tilvis R. Factors associated with calcific aortic valve degeneration in the elderly. Eur Heart J. 1994;15(7):865–70.PubMed

14.

Cuniberti LA, Stutzbach PG, Guevara E, Yannarelli GG, Laguens RP, Favaloro RR. Development of mild aortic valve stenosis in a rabbit model of hypertension. J Am Coll Cardiol. 2006;47(11):2303–9.PubMedCrossRef

15.

Jian B, Narula N, Li QY, Mohler III ER, Levy RJ. Progression of aortic valve stenosis: TGF-beta1 is present in calcified aortic valve cusps and promotes aortic valve interstitial cell calcification via apoptosis. Ann Thorac Surg. 2003;75:457–65.PubMedCrossRef

16.

Kaden JJ, Dempfle CE, Grobholz R, et al. Interleukin-1beta promotes matrix metalloproteinase expression and cell proliferation in calcific aortic valve stenosis. Atherosclerosis. 2003;170:205–11.PubMedCrossRef

17.

Satta J, Melkko J, Pollanen R, et al. Progression of human aortic valve stenosis is associated with tenascin-C expression. J Am Coll Cardiol. 2002;39:96–101.PubMedCrossRef

18.

Mackie EJ, Scott-Burden T, Hahn AW, et al. Expression of tenascin by vascular smooth muscle cells. Alterations in hypertensive rats and stimulation by angiotensin II. Am J Pathol. 1992;141(2):377–88.PubMed

19.

Touyz RM. Reactive oxygen species, vascular oxidative stress, and redox signaling in hypertension: what is the clinical significance? Hypertension. 2004;44(3):248–52.PubMedCrossRef

20.

Liberman M, Bassi E, Martinatti MK, et al. Oxidant generation predominates around calcifying foci and enhances progression of aortic valve calcification. Arterioscler Thromb Vasc Biol. 2008;28:463–70.PubMedCrossRef

21.

O'Brien KD, Shavelle DM, Caulfield MT, et al. Association of angiotensin converting enzyme with low-density lipoprotein in aortic valvular lesions and in human plasma. Circulation. 2002;106:2224–30.PubMedCrossRef

22.

Helske S, Syvaranta S, Kupari M, et al. Possible role for mast cell-derived cathepsin G in the adverse remodelling of stenotic aortic valves. Eur Heart J. 2006;27:1495–504.PubMedCrossRef

23.

Ngo DT, Heresztyn T, Mishra K, Marwick TH, Horowitz JD. Aortic stenosis is associated with elevated plasma levels of asymmetric dimethylarginine (ADMA). Nitric Oxide. 2007;16:197–201.PubMedCrossRef

24.

Tsakiris A, Doumas M, Nearchos N, Mavrokefalos A, Mpatakis N, Skoufas P. Aortic calcification is associated with age and sex but not left ventricular mass in essential hypertension. J Clin Hypertens. 2004;6:65–70.CrossRef

25.

Helske S, Lindstedt KA, Laine M, et al. Induction of local angiotensin II-producing systems in stenotic aortic valves. J Am Coll Cardiol. 2004;44(9):1859–66.PubMedCrossRef

26.

Jensen LW, Bagger JP, Pedersen EB. Twenty-four-hour ambulatory blood pressure and vasoactive hormones in valvular aortic disease. Blood Press. 1996;5(5):292–9.PubMedCrossRef

27.

Stewart BF, Siscovick D, Lind BK, et al. Clinical factors associated with calcific aortic valve disease: Cardiovascular Health Study. J Am Coll Cardiol. 1997;29:630–4.PubMedCrossRef

28.

•• Rieck AE, Cramariuc D, Staal EM, Rossebø AB, Wachtell K, Gerdts E. Impact of hypertension on left ventricular structure in patients with asymptomatic aortic valve stenosis (a SEAS substudy). J Hypertens. 2010;28(2):234–6. This paper outlines the differences between left ventricle hypertrophy induced by arterial hypertension and AVS.CrossRef

29.

Antonini-Canterin F, Huang G, Cervesato E, et al. Reliability of new and old Doppler echocardiographic indexes of the severity of aortic stenosis in patients with a low cardiac output. Ital Heart J. 2002;3(4):248–55.PubMed

30.

• Tuseth N, Cramariuc D, Rieck AE, Wachtell K, Gerdts E. Asymmetric septal hypertrophy - a marker of hypertension in aortic stenosis (a SEAS substudy). Blood Press. 2010;19(3):140–4. This paper outlines the differences between left ventricle hypertrophy induced by arterial hypertension and AVS.PubMedCrossRef

31.

• Ashikhmina EA, Schaff HV, Dearani JA, Sundt III TM, Suri RM, Park SJ, et al. Aortic valve replacement in the elderly: determinants of late outcome. Circulation. 2011;124(9):1070–8. This paper demonstrates that hypertension may unfavorably affect the prognosis of these patients and is one of the independent predictors of death after aortic valve replacement.PubMedCrossRef

32.

Cramariuc D, Gerdts E, Segadal L. Impact of hypertension on left ventricular hypertrophy regression and exercise capacity in patients operated for aortic valve stenosis. Scand Cardiovasc J. 2006;40(3):167–74.PubMedCrossRef

33.

Vánky FB, Håkanson E, Tamás E, Svedjeholm R. Risk factors for postoperative heart failure in patients operated on for aortic stenosis. Ann Thorac Surg. 2006;81(4):1297–304.PubMedCrossRef

34.

•• Thomas M, Schymik G, Walther T, et al. One-year outcomes of cohort 1 in the Edwards SAPIEN Aortic Bioprosthesis European Outcome (SOURCE) registry: the European registry of transcatheter aortic valve implantation using the Edwards SAPIEN valve. Circulation. 2011;124(4):425–33. This study showed that hypertensive patients have a “lower hypertrophy reduction” and worse clinical outcome.PubMedCrossRef

35.

Imanaka K, Kohmoto O, Nishimura S, Yokote Y, Kyo S. Impact of postoperative blood pressure control on regression of left ventricular mass following valve replacement for aortic stenosis. Eur J Cardiothorac Surg. 2005;27(6):994–9.PubMedCrossRef

36.

Faggiano P, Sabatini T, Rusconi C, Ghizzoni G, Marchetti A, Sorgato A. Left ventricular geometric adaption to chronic pressure overload: differences between systemic hypertension and valvular aortic stenosis: an echocardiographic study. Am J Noninvas Cardiol. 1994;8:346–51.

37.

Strotmann JM, Lengenfelder B, Blondelot J, et al. Functional differences of left ventricular hypertrophy induced by either arterial hypertension or aortic valve stenosis. Am J Cardiol. 2008;101:1493–7.PubMedCrossRef

38.

Schwartzkopff B, Frenzel H, Dieckerhoff J, et al. Morphometric investigation of human myocardium in arterial hypertension and valvular aortic stenosis. Eur Heart J. 1992;13(suppl):17–23.PubMedCrossRef

39.

Krayenbuehl HP, Hess OM, Monrad ES, Schneider J, Mall G, Turina M. Function and structure of the failing left ventricular myocardium in aortic valve disease before and after valve replacement. Basic Res Cardiol. 1991;86(suppl):175–85.PubMed

40.

Li JK, Zhu JY, Nanna M. Computer modeling of the effects of aortic valve stenosis and arterial system afterload on left ventricular hypertrophy. Comput Biol Med. 1997;27(6):477–85.PubMedCrossRef

41.

Garcia D, Pibarot P, Kadem L, Durand LG. Respective impacts of aortic stenosis and systemic hypertension on left ventricular hypertrophy. J Biomech. 2007;40(5):972–80.PubMedCrossRef

42.

Kadem L, Dumensil J, Rieu R, Durand LG, Garcia D, Pibarot P. Impact of systemic hypertension on the assessment of aortic stenosis. Heart. 2005;91:354–61.PubMedCrossRef

43.

Razzolini R, Gerosa G, Leoni L, Casarotto D, Chioin R, Dalla-Volta S. Transaortic gradient is pressure-dependent in a pulsatile model of the circulation. Hypertens J Heart Valve Dis. 1999;8(3):279–83.

44.

Mascherbauer J, Fuchs C, Stoiber M, et al. Systemic pressure does not directly affect pressure gradient and valve area estimates in aortic stenosis in vitro. Eur Heart J. 2008;29:2049–57.PubMedCrossRef

45.

Little SH, Chan KL, Burwash IG. Impact of blood pressure on the Doppler echocardiographic assessment of severity of aortic stenosis. Heart. 2007;93:848–55.PubMedCrossRef

46.

Otto CM, Burwash IG, Legget ME, et al. Prospective study of asymptomatic valvular aortic stenosis. Clinical, echocardiographic, and exercise predictors of outcome. Circulation. 1997;95:2262–70.PubMedCrossRef

47.

Khot UN, Novaro GM, Popović ZB, et al. Nitroprusside in critically ill patients with left ventricular dysfunction and aortic stenosis. N Engl J Med. 2003;348(18):1756–63.PubMedCrossRef

48.

Fielitz J, Hein S, Mitrovic V, et al. Activation of the cardiac renin-angiotensin system and increased myocardial collagen expression in human aortic valve disease. J Am Coll Cardiol. 2001;37(5):1443–9.PubMedCrossRef

49.

O’Brien KD, Zhao XQ, Shavelle DM, et al. Hemodynamic effects of the angiotensin-converting enzyme inhibitor, ramipril, in patients with mild to moderate aortic stenosis and preserved left ventricular function. J Investig Med. 2004;52:185–91.PubMedCrossRef

50.

Arishiro K, Hoshiga M, Negoro N, et al. Angiotensin receptor-1 blocker inhibits atherosclerotic changes and endothelial disruption and rapid progression of aortic dilatation in patients with bicuspid aortic valves. Nat Clin Pract Cardiovasc Med. 2008;5:821–8.CrossRef

51.

•• Ngo DT, Stafford I, Sverdlov AL, et al. Ramipril retards development of aortic valve stenosis in a rabbit model: mechanistic considerations. Br J Pharmacol. 2011;162:722–32. This paper demonstrates that treatment with ACEi inhibitors has beneficial results in calcification and macrophage infiltration, improves endothelial function, and retards the development of AVS.PubMedCrossRef

52.

Simolin MA, Pedersen TX, Bro S, et al. ACE inhibition attenuates uremia-induced aortic valve thickening in a novel mouse model. BMC Cardiovasc Disord. 2009;9:10.PubMedCrossRef

53.

O'Brien KD, Probstfield JL, Caulfield MT, et al. Angiotensin-converting enzyme inhibitors and change in aortic valve calcium. Arch Intern Med. 2005;165:858–62.PubMedCrossRef

54.

Jiménez-Candil J, Bermejo J, Yotti R, et al. Effects of angiotensin converting enzyme inhibitors in hypertensive patients with aortic valve stenosis: a drug withdrawal study. Heart. 2005;91(10):1311–8.PubMedCrossRef

55.

Rosenhek R, Rader F, Loho N, et al. Statins but not angiotensin-converting enzyme inhibitors delay progression of aortic stenosis. Circulation. 2004;110:1291–5.PubMedCrossRef

56.

• Wakabayashi K, Tsujino T, Naito Y, et al. Administration of angiotensin-converting enzyme inhibitors is associated with slow progression of mild aortic stenosis in Japanese patients. Hear Vessel. 2011;26(3):252–7. This paper demonstrates that treatment with ACEi inhibitors has beneficial results in calcification and macrophage infiltration, improves endothelial function, and retards the development of AVS.CrossRef

57.

Dahl JS, Videbaek L, Poulsen MK, et al. Effect of candesartan treatment on left ventricular remodeling after aortic valve replacement for aortic stenosis. Am J Cardiol. 2010;106(5):713–9.PubMedCrossRef

58.

Aggeli C, Lampropoulos K, STefanadis C. Aortic Stenosis and Hypertension: Is there any relationship? Hellenic J Cardiol. 2009;50:1–2.PubMed

Title: Aortic Valve Stenosis and Arterial Hypertension: A Synopsis in 2013
Authors: Vasiliki Katsi
Maria Marketou
Manolis S. Kallistratos
Thomas Makris
Athanasios J. Manolis
Dimitris Tousoulis
Christodoulos Stefanadis
Panos Vardas
Ioannis Kallikazaros
Publication date: 01-08-2013
Publisher: Springer US
Published in: Current Hypertension Reports / Issue 4/2013
Print ISSN: 1522-6417
Electronic ISSN: 1534-3111
DOI: https://doi.org/10.1007/s11906-013-0357-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2013

Fructose-Containing Sugars, Blood Pressure, and Cardiometabolic Risk: A Critical Review

Gender Differences in Hypertension: Myths and Reality

Revelations About Carotid Body Function Through its Pathological Role in Resistant Hypertension

The Sympathetic Nervous System in Chronic Kidney Disease

Primary Hypertension in Children and Adolescents is an Immuno-Metabolic Disease with Hemodynamic Consequences

The Role of Home Blood Pressure Telemonitoring in Managing Hypertensive Populations

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials